Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set.

Molecular cancer therapeutics - 1 Feb 2010

Park Eun Sung, Rabinovsky Rosalia, Carey Mark, Hennessy Bryan T, Agarwal Roshan, Liu Wenbin, Ju Zhenlin, Deng Wanleng, Lu Yiling, Woo Hyun Goo, Kim Sang-Bae, Cheong Jae-Ho, Garraway Levi A, Weinstein John N, Mills Gordon B, Lee Ju-Seog, Davies Michael A

Abstract excerpt

Aberrations in oncogenes and tumor suppressors frequently affect the activity of critical signal transduction pathways. To analyze systematically the relationship between the activation status of protein networks and other characteristics of cancer cells, we did reverse phase protein array (RPPA) profiling of the NCI60 cell lines for total protein expression and activation-specific markers of critical signaling...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cluster Analysis

Share to Drug Screening Assays, Antitumor

Share to Mutation

Share to Proteomics

Share to Signal Transduction

Share to United States

Source

Open in PubMed Open full text

Identifiers

PMID: 20124458
DOI: 10.1158/1535-7163.MCT-09-0743
PMCID: PMC4085051

Genes

PTEN
APC
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set.PMID 20124458Read ↗

Rapid proteotyping reveals cancer biology and drug response determinants in the NCI-60 cellsSemantic proximity Read ↗

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.Semantic proximity Read ↗

Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines.Semantic proximity Read ↗

Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays.Semantic proximity Read ↗

Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60.Semantic proximity Read ↗

Comparative analysis and integrative classification of NCI60 cell lines and primary tumors using gene expression profiling dataSemantic proximity Read ↗

Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery.Semantic proximity Read ↗

Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell LinesSemantic proximity Read ↗

Quantitative phosphoproteomic analysis of the PI3K-regulated signaling network.Semantic proximity Read ↗

RNA Sequencing of the NCI-60: Integration into CellMiner and CellMiner CDBSemantic proximity Read ↗

Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines.Semantic proximity Read ↗

Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.